Accelerate your Live Biotherapeutic Product (LBP) development with faster iteration in fermentation, formulation, and batch comparison. We deliver rapid viability and enumeration readouts within a shorter turnaround, featuring custom method setup with live/dead gating and optional target-specific labeling. Outputs include CFU correlation, documented gating strategies, batch consistency analysis, and supported sample types.
For teams rapidly iterating on fermentation processes, lyophilization formulations, or evaluating complex Live Biotherapeutic Products (LBPs), traditional Colony Forming Unit (CFU) plating often presents critical pain points:
Creative Biolabs leverages multiparametric Flow Cytometry (FCM) to resolve these bottlenecks. By analyzing single cells in suspension at rates of thousands of events per second, FCM serves as a rapid complementary method to traditional plating, providing quantification of distinct cellular states within hours.
Rather than completely replacing CFU workflows, our service is designed to function as an orthogonal enumeration strategy. We help clients establish robust FCM gating, ensuring rapid readouts during development, while providing the necessary correlation data to bridge back to established release criteria.
We establish a clear, actionable methodology tailored to your project. When you partner with us for flow cytometric evaluation, your final technical report and data package will explicitly include:
Customized sample disaggregation and staining protocols optimized specifically for your target strains, ensuring minimal background noise and maximum signal resolution.
Clear, reproducible bivariate dot plots and analytical logic discriminating live, dead, and injured (VBNC) populations using validated dual-staining (e.g., SYTO 24/PI).
For complex multi-strain blends or microbiomes, integration of target-specific fluorophore-conjugated antibodies to accurately enumerate your specific strain against a complex background.
Statistical models and correlation graphs bridging the rapid FCM total viable counts with your established CFU plating workflows across various growth phases or stress conditions.
Evaluation of production robustness, offering statistical variation summaries to help you rapidly compare lot-to-lot viability and stability during formulation optimization.
The core deliverable: absolute event counts (e.g., quantified viable cells/mL) and highly accurate viability percentages reflecting the true functional biomass of your product.
We understand that LBP development involves testing across various stages of manufacturing. Our methods can be tailored to accommodate diverse matrices, with specific sample preparation recommendations provided based on aggregation, background fluorescence, and matrix complexity.
Shift from 3-day CFU plating waits to same-day actionable data, empowering immediate adjustments in fermentation runs and formulation screening.
Accurately identify live, dead, and injured (VBNC) cells simultaneously, providing a more precise picture of biological activity post-processing.
We don't just provide new data; we integrate it. We build statistical correlations to your existing plating methods for smooth regulatory and QA transitions.
From difficult-to-disaggregate anaerobes to multi-strain commercial blends requiring antibody gating, our strategies are custom-designed per project.
Flow Cytometry is increasingly adopted in development and quality evaluation workflows because it resolves the specific limitations of traditional methodologies—particularly in complex, multi-strain environments.
Why flow cytometry is useful for rapid evaluation: Traditional plate counts often fail to accurately distinguish individual species within a multi-strain blend due to competitive inhibition and overlapping morphological features. Furthermore, plating entirely misses the VBNC population induced by manufacturing stressors.
By measuring parameters such as side scatter (SSC) and specific fluorescence (e.g., SYTO 24 and Propidium Iodide), researchers can rapidly and effectively isolate distinct sub-populations representing live, dead, and injured cells within a heterogeneous mixture.
As demonstrated in recent literature by Tracey et al. (2023), establishing a robust gating strategy (illustrated left) successfully detects these metabolically active but non-culturable cells, providing a much more precise reflection of the product's true biological potential and enabling faster batch comparison.
Our CRO services integrate these proven principles. We establish and validate specific gating strategies tailored to your unique LBPs, ensuring your quantitative data is scientifically rigorous and readily actionable.
From initial method development to routine sample testing, our standardized workflow guarantees accuracy, speed, and transparency.
Review target strains, matrix complexity, and iteration goals to design the optimal staining panel and prepare for potential CFU bridging.
Optimization of cell disaggregation techniques (crucial for clumps/chains) and titration of fluorescent dyes to ensure maximum signal-to-noise ratio.
Running heat-killed and exponential-phase controls to clearly delineate boundaries for live, injured, and dead populations using analytical software.
High-throughput processing of test samples alongside traditional plate counts (if required) to build the required CFU correlation matrices.
Delivery of a detailed report including documented gating logic, correlation graphs, absolute counts, and interpretation of viability status for batch comparison.
Beyond Flow Cytometry, Creative Biolabs offers a comprehensive suite of analytical assays designed to support the entire lifecycle of Live Biotherapeutic Products. From genetic identification to functional bioassays, explore our highly integrated solutions to accelerate your research and IND-enabling studies:
FCM provides a much faster, orthogonal assessment that supports day-to-day iteration. While CFU plating remains essential for historical data and standard release criteria, it takes days and misses VBNC populations. FCM analyzes individual cells in minutes, differentiating live, dead, and injured populations based on membrane integrity. It provides rapid viability percentages that can be correlated back to your CFU workflows, significantly accelerating formulation screening and bioprocess decisions.
To construct an accurate technical proposal and begin method setup, we ideally need to know the target strain(s) or species, the intended sample matrix (e.g., washed cells, lyophilizate, complex fermentation broth), any known aggregation tendencies, and whether you require bridging studies to existing release methodologies (like specific CFU plating protocols).
Yes. For single strains or simple evaluations, universal live/dead dyes (e.g., SYTO 24/PI) are highly effective. For multi-strain commercial blends where you need to track the viability of a specific targeted strain against a complex background, we can achieve specificity by integrating fluorophore-conjugated primary and secondary antibodies into the FCM gating strategy.
Your final report will detail the finalized sample preparation methodology, the documented gating logic (supported by representative bivariate cytograms), absolute viability percentages and event counts, batch consistency evaluations (if applicable), and optionally, the statistical correlation graphs demonstrating how the FCM data bridges to your standard CFU outputs.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.